NCT06815133 Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis Over 3 Months
| NCT ID | NCT06815133 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Condition | Myasthenia Gravis |
| Study Type | OBSERVATIONAL |
| Enrollment | 55 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2026-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 55 participants in total. It began in 2025-03-01 with a primary completion date of 2026-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study called "Multicenter Retrospective Study on the Short- and Medium-Term Efficacy and Tolerance of Zilucoplan Therapy in a Cohort of French Patients with Anti-AChR Myasthenia Gravis", is investigating the effects of a new treatment called Zilucoplan (generic name: ZILBRYSQ) on patients in France with a condition known as myasthenia gravis. Myasthenia gravis is an autoimmune disease that causes muscle weakness that worsens throughout the day with activity and impacts the ability to work and perform daily activities. The study aims to see if Zilucoplan can improve muscle strength and quality of life over three months, while also assessing its tolerance and safety by monitoring side effects. Researchers hope this treatment will offer significant benefits for people with this challenging condition.
Eligibility Criteria
Inclusion Criteria: \- Confirmed diagnosis of myasthenia gravis with anti-AChR antibodies in patients treated with Zilucoplan Exclusion Criteria: * None
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06815133 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myasthenia Gravis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06815133 currently recruiting?
Yes, NCT06815133 is actively recruiting participants. Contact the research team at sacconi.s@chu-nice.fr for enrollment information.
Where is the NCT06815133 trial being conducted?
This trial is being conducted at Nice, France.
Who is sponsoring the NCT06815133 clinical trial?
NCT06815133 is sponsored by Centre Hospitalier Universitaire de Nice. The trial plans to enroll 55 participants.